Fulminant type 1 diabetes caused by peginterferon α-2a therapy in hepatitis C
丙型肝炎患者使用聚乙二醇干扰素α-2a治疗后导致的暴发性1型糖尿病
Ying Zheng
Center for Medical Research, Second Xiangya Hospital, Central South University, Changsha, China
Search for more papers by this authorZhen Wang
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Search for more papers by this authorZhiguo Xie
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Search for more papers by this authorRuchun Dai
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Search for more papers by this authorCorresponding Author
Zhiguang Zhou
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Correspondence
Zhiguang Zhou, 139 Renmin Road, Changsha, Hunan 410011, China.
Tel: +86 731 8529 5890
Fax: +86 731 8529 5890
Email: [email protected]
Search for more papers by this authorYing Zheng
Center for Medical Research, Second Xiangya Hospital, Central South University, Changsha, China
Search for more papers by this authorZhen Wang
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Search for more papers by this authorZhiguo Xie
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Search for more papers by this authorRuchun Dai
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Search for more papers by this authorCorresponding Author
Zhiguang Zhou
Department of Metabolism and Endocrinology, Second Xiangya Hospital and Diabetes Center, Institute of Metabolism and Endocrinology, Central South University, Changsha, China
Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, Changsha, China
Correspondence
Zhiguang Zhou, 139 Renmin Road, Changsha, Hunan 410011, China.
Tel: +86 731 8529 5890
Fax: +86 731 8529 5890
Email: [email protected]
Search for more papers by this author
References
- 1Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. N Engl J Med. 2000; 342: 301–307.
- 2Imagawa A, Hanafusa T, Awata T et al. Report of the Committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: New diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012; 3: 536–539.
- 3Nakamura K, Kawasaki E, Imagawa A et al. Type 1 diabetes and interferon therapy: A nationwide survey in Japan. Diabetes Care. 2011; 34: 2084–2089.
- 4Zheng C, Zhou Z, Yang L et al. Fulminant type 1 diabetes mellitus exhibits distinct clinical and autoimmunity features from classical type 1 diabetes mellitus in Chinese. Diabetes Metab Res Rev. 2011; 27: 70–78.
- 5Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T. Class II HLA genotype in fulminant type 1 diabetes: A nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012; 3: 62–69.
Citing Literature
